Description

(R)-(+)-Dropropizine CAS NO 99291-24-4 is the pharmacologically active enantiomer of the antitussive agent dropropizine, characterized by its high stereochemical purity. This compound is of significant value in the development and manufacturing of advanced pharmaceutical formulations targeting cough suppression with potentially improved efficacy and reduced side-effect profiles. It is primarily required by pharmaceutical R&D laboratories and manufacturers specializing in enantiomerically pure active pharmaceutical ingredients (APIs) for respiratory therapeutics.

Application

• Pharmaceutical Intermediate: Serves as a key chiral building block in the synthesis of advanced antitussive drugs.
• Active Pharmaceutical Ingredient (API) Development: Used in R&D for formulating new enantiomerically pure cough suppressant medications.
• Pharmacological Research: Employed in preclinical and clinical studies to investigate the specific activity, metabolism, and safety profile of the (R)-enantiomer.
• Reference Standard: Acts as a high-purity certified reference material (CRM) for analytical method development and quality control in pharmaceutical analysis.
• Stereochemistry Studies: Utilized in academic and industrial research focused on chiral pharmacology and the impact of enantiopurity on drug action.

Basic Information

Product Name	(R)-(+)-Dropropizine
CAS No.	99291-24-4
Molecular Formula	C13H20N2O2
Molecular Weight	236.31 g/mol
Synonyms	(R)-(+)-Dropropizine; (R)-Dropropizine; (+)-Dropropizine; (R)-1-(2-Piperidin-1-ylethoxy)-3-(1H-pyrrol-1-yl)propan-2-ol; (R)-(-)-3-(1-Pyrrolyl)-1-(2-piperidinoethoxy)-2-propanol; Levodropropizine (Note: Levodropropizine is the INN for the (R)-(-) enantiomer of the related compound); (R)-(-)-Dropropizine (alternate naming); S-(-)-Dropropizine (alternate stereochemical descriptor)
EINECS	Contact for details

Quality Control

Our (R)-(+)-Dropropizine is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including chiral purity assay and impurity profiling, to ensure it meets stringent specifications for pharmaceutical research and development. A Certificate of Analysis (COA) detailing identity, purity (HPLC), enantiomeric excess, and related substances is provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). The product is light-sensitive and should be handled under appropriate conditions to maintain stability.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Enantiomeric Excess (Chiral HPLC)	≥99.0%
Related Substances (HPLC)	Total impurities ≤2.0% Any single impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.